Research digest / pharmacokinetics
Sermorelin Half-Life and Pharmacokinetics
A short line with a fast clearance: roughly 10-12 minutes in plasma, yet about 3 hours of growth-hormone elevation — and why that brevity drove the longer-acting analogs.
The short version
The sermorelin half-life is short. After an intravenous dose, the peptide clears from the blood in about 10-12 minutes — the body breaks it down quickly. Yet the effect outlasts the molecule: a single dose keeps growth hormone elevated for roughly 3 hours, because the brief GHRH signal is enough to trigger a longer pituitary response. That short clearance is also why chemists built longer-acting versions (like CJC-1295, especially with its DAC tag): they wanted the signal to persist without redosing. "Bioavailability" below just means the fraction of a dose that actually reaches the bloodstream.
The plasma half-life and clearance
GHRH(1-29) has a short plasma half-life on the order of about 10-12 minutes after intravenous administration and is rapidly eliminated [3]. That brevity is intrinsic to the native sequence — short peptides are quickly degraded by circulating enzymes. The pharmacokinetic study that established the profile dosed 30 healthy men intravenously, seeing significant GH release at doses as low as 0.25 mcg/kg and maximal release at 1-2 mcg/kg [3]. The molecule leaves the blood fast; what it sets in motion does not.
Why GH stays up for hours after a minutes-long peptide
Despite that rapid clearance, a single GHRH(1-29) dose keeps serum GH elevated for roughly 3 hours [3]. The reason is mechanistic: sermorelin is a trigger, not the payload. It tells the pituitary to release and synthesize its own GH, and that pituitary output — followed by the slower downstream rise in IGF-1 — persists well beyond the few minutes the peptide itself survives [14]. This decoupling of drug half-life from effect duration is exactly why GH elevation, not plasma persistence, is the meaningful readout.
Route and bioavailability
Route changes how much drug arrives. Subcutaneous injection is the primary research route [1][2]; the intravenous route was used for the pharmacokinetic and diagnostic work [3]. The intranasal route was tested historically and performed poorly — bioavailability was only about 3-5%, so the great majority of an intranasal dose never reached circulation [3]. That low mucosal uptake is consistent with the wider observation that oral and sublingual peptide products are degraded before they can act, and it is part of why the injectable forms dominate the literature.
Why the short half-life motivated longer-acting analogs
The native peptide's brevity is the engineering problem the field set out to solve. A roughly 10-12 minute plasma half-life means the GHRH signal is gone almost as soon as it arrives, so chemists stabilized the molecule: a D-Ala2 substitution resists enzymatic breakdown, and the DAC (Drug Affinity Complex) technology behind CJC-1295 binds serum albumin to extend the half-life by days [3]. Tesamorelin is another stabilized GHRH analog studied for its longer, steadier action [11]. The trade-off is pattern: sermorelin gives a short, physiologic pulse close to the body's own rhythm, while the long-acting analogs trade that pulse for duration.
Pulse versus plateau: the design choice the numbers force
The half-life numbers turn into a design choice. A short, minutes-long clearance produces a sharp GH pulse that rises and falls — close to the body's own nightly secretory burst, where the GH/IGF-1 axis is built to operate, with the somatostatin brake and IGF-1 feedback both able to act between pulses [4][14]. A days-long half-life (CJC-1295 with DAC) produces a flatter, more continuous elevation that departs from that natural rhythm [3]. Neither is automatically "better"; they answer different questions. The physiology literature is one reason the pulse matters: pulsatile GH secretion specifically helps regulate lipolysis in fasting humans, an effect tied to the bursts rather than to a steady level [7]. So sermorelin's short half-life is not only a limitation to engineer around — it is also what keeps its signal physiologic, which is the property the secretagogue argument was built on [4].
How the clearance was actually measured
The half-life figure is not a guess — it comes from direct measurement. The pharmacokinetic study administered GHRH(1-29)NH2 to 30 healthy men and tracked both the peptide's disappearance from plasma and the GH it elicited, across intravenous and intranasal routes [3]. That design is what separates the two timescales cleanly: it could show the peptide clearing in about 10-12 minutes while serum GH stayed up for roughly 3 hours, and it could quantify how little of an intranasal dose (~3-5%) ever reached the blood [3]. When a number on this site says "plasma half-life," it traces to that kind of measured clearance, not to an estimate.
What is sermorelin's half-life and how long does it stay in your system?
GHRH(1-29) has a short plasma half-life on the order of about 10-12 minutes after intravenous dosing and is rapidly cleared, yet a single dose can keep serum GH elevated for roughly 3 hours [3]. Its brevity — the molecule itself is gone within minutes — is precisely what motivated the longer-acting analogs like CJC-1295 and tesamorelin [11].